Js. Li et al., RENAL AND VASCULAR EFFECTS OF CHRONIC ENDOTHELIN RECEPTOR ANTAGONISM IN MALIGNANT HYPERTENSIVE RATS, American journal of hypertension, 9(8), 1996, pp. 803-811
The effect of the combined ET(A)/ET(B) endothelin receptor antagonist
bosentan on blood pressure, vascular hypertrophy, and pathologic renal
changes was investigated in a model of malignant hypertension, severe
vascular hypertrophy, and enhanced vascular expression of endothelin-
1, the deoxycorticosterone acetate (DOCA), and salt-treated spontaneou
sly hypertensive rat (SHR). DOCA-salt treated SHR received 100 mg bose
ntan per kilogram weight per day mixed with their food. Systolic blood
pressure of untreated DOCA-salt SHR rose to 241 +/- 1.5 mm Hg, wherea
s that of bosentan-treated rats rose to 221 +/- 5.1 mm Hg (P < .01). C
ardiac and conduit artery mass were not affected by treatment. Small a
rteries from the coronary, renal, and mesenteric circulations showed a
smaller media width and cross-sectional area of the media in rats tre
ated with bosentan than in untreated rats. The kidneys showed the pres
ence of fibrinoid necrosis in a high percentage of afferent arterioles
and glomeruli of untreated DOCA-SHR. Some kidneys of treated rats exh
ibited less severe vascular hypertrophy and lesser extent of vascular
or glomerular fibrinoid necrosis, but the renal injury score of bosent
an-treated DOCA-SHR was only at the limit of significance from that of
untreated rats (P = .06). These results suggest a role for endothelin
-l in blood pressure elevation and the severe vascular hypertrophy of
small arteries of the coronary, renal, and mesenteric vasculature, but
not of the heart or larger conduit vessels in the malignant hypertens
ion that SHR develop after treatment with DOCA and salt. Although some
bosentan-treated rats showed fewer renal lesions, a significant effec
t on renal pathology could not be unambiguously demonstrated. Further
studies will be necessary to determine whether endothelin antagonists
may indeed offer some degree of renal protection and have therapeutic
potential in severe or malignant hypertension.